Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth.

Autor: Liu L; Biotechnology Discovery Research, Liu_Ling@lilly.com., Zeng W; Biotechnology Discovery Research., Wortinger MA; Biotechnology Discovery Research., Yan SB; Oncology Discovery Research., Cornwell P; Toxicology., Peek VL; Oncology Discovery Research., Stephens JR; Oncology Discovery Research., Tetreault JW; Biotechnology Discovery Research., Xia J; Biotechnology Discovery Research., Manro JR; Discovery Statistics., Credille KM; Diagnostic Experimental Pathology., Ballard DW; Diagnostic Experimental Pathology., Brown-Augsburger P; Drug Disposition., Wacheck V; Oncology Medical., Chow CK; Biotechnology Discovery Research., Huang L; Bioproduct Research and Development., Wang Y; Discovery Chemistry Research and Technologies. Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana., Denning I; Biotechnology Discovery Research., Davies J; Biotechnology Discovery Research., Tang Y; Biotechnology Discovery Research., Vaillancourt P; Biotechnology Discovery Research., Lu J; Biotechnology Discovery Research.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2014 Dec 01; Vol. 20 (23), pp. 6059-70. Date of Electronic Publication: 2014 Sep 17.